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ABSTRACT For enteroviruses such as poliovirus (PV), empty capsids, which are anti-
genically indistinguishable from mature virions, are produced naturally during viral
infection. The production of such capsids recombinantly, in heterologous systems
such as yeast, have great potential as virus-like particle (VLP) vaccine candidates.
Here, using PV as an exemplar, we show the production of VLPs in Pichia pastoris by
coexpression of the structural precursor protein P1 and the viral protease 3CD. The
level of expression of the potentially cytotoxic protease relative to that of the P1
precursor was modulated by three different approaches: expression of the P1 pre-
cursor and protease from different transcription units, separation of the P1 and pro-
tease proteins using the Thosea asigna virus (TaV) 2A translation interruption se-
quence, or separation of the P1 and protease-coding sequences by an internal
ribosome entry site sequence from Rhopalosiphum padi virus (RhPV). We also investi-
gate the antigenicity of VLPs containing previously characterized mutations when
produced in Pichia. Finally, using transmission electron microscopy and two-
dimensional classiﬁcation, we show that Pichia-derived VLPs exhibited the classical
icosahedral capsid structure displayed by enteroviruses.
IMPORTANCE Although the current poliovirus immunization program has been ex-
tremely successful in reducing the number of cases of paralytic polio worldwide,
now more cases are caused by vaccine-derived polioviruses than by wild poliovirus.
Switching to inactivated poliovirus vaccines will reduce this over time; however,
their production requires the growth of large amounts of virus. This biosafety con-
cern can be addressed by producing just the virus capsid. The capsid serves to pro-
tect the genetic material, which causes disease when introduced into a cell. There-
fore, empty capsids (virus-like particles [VLPs]), which lack the viral RNA genome, are
safe both to make and to use. We exploit yeast as a versatile model expression sys-
tem to produce VLPs, and here we speciﬁcally highlight the potential of this system
to supply next-generation poliovirus vaccines to secure a polio-free world for the fu-
ture.
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Enteroviruses are responsible for a number of human and animal diseases, withpoliovirus (PV) being the best-characterized member. PV is the causative agent of
poliomyelitis, a devastating paralytic and sometimes fatal infection that was responsi-
ble for global epidemics in the last century. However, since the introduction of the
Global Polio Eradication Initiative in 1988, there has been a 99% reduction in the
number of cases worldwide, with wild-type (wt) poliovirus now only endemic to
Afghanistan, Pakistan, and Nigeria (http://polioeradication.org/polio-today/polio-now/).
This reduction is primarily attributable to the use of two highly effective vaccines, the
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live-attenuated oral PV vaccine (OPV) and the inactivated PV vaccine (IPV), both of
which target all three PV serotypes (PV-1, PV-2, and PV-3). wt PV-2 has been declared
globally eradicated, as none has been isolated since 1999 (1). However, despite the
success of these vaccines, there are signiﬁcant safety concerns for their continued use
in a “polio-free” world to guard against the potential catastrophe that would result from
the reintroduction of the virus.
Due to the genetic instability of OPV, the attenuated virus can quickly revert to
virulence, leading to vaccine-associated paralytic poliomyelitis (VAPP), especially in
areas of low vaccine coverage, leading to circulating vaccine-derived PV (cVDPV)
(2). Indeed, cVDPV cases now outnumber wt PV-derived cases worldwide (http://
polioeradication.org/polio-today/polio-now/). Additionally, individuals with undiag-
nosed compromised immune systems may become chronic carriers of cVDPV postvac-
cination, acting as reservoirs capable of reintroducing PV to the environment (2, 3).
Although IPV offers effective protection against polio disease, it does not prevent the
replication of the virus in infected individuals and, therefore, cannot halt further
transmission of the virus within a population (4). Furthermore, the production of IPV
requires the growth of large amounts of highly concentrated infectious virus, which
could be catastrophic in the event of accidental release (https://www.ecdc.europa.eu/
en/threats-and-outbreaks).
PV is a positive-sense RNA virus, belonging to the species Enterovirus C, with a 7.5-kb
genome that contains 2 overlapping reading frames. The recently discovered small
open reading frame (ORF) of unknown function has been shown to be important for
replication in ex vivo human enteroids (5). The major ORF (Fig. 1A) is translated as a
single large polyprotein that is proteolytically cleaved into the mature viral proteins (5,
6). The viral protease 3C and its precursor, 3CD, play key roles in viral replication. 3C is
responsible for the processing of the P2 and P3 regions of the viral polyprotein,
whereas 3CD has been shown in vitro to be responsible primarily for cleavage of the
structural precursor protein P1 (7, 8). Additionally, 3CD also has been shown to have an
integral role in priming the viral RNA for replication by the viral polymerase 3D (9, 10).
P1 is processed to produce the capsid proteins VP0, VP3, and VP1, with the subsequent
cleavage of VP0 into VP2 and VP4 thought to be driven by the encapsidation of the viral
genome (11, 12). Mature PV virions contain 60 copies of each of VP1 to VP4, forming
an 30-nm icosahedral capsid (13). In addition, PV infection also leads to the produc-
tion of empty capsids (ECs), which lack the viral genome but are otherwise identical to
the mature virions, except that they contain uncleaved VP0 (14). Recombinantly
expressed ECs could be developed as a virus-like particle (VLP) vaccine to replace the
current vaccines against PV. However, wt ECs are inherently unstable, resulting in a
conformational expansion of the particles and conversion from native antigenicity
(termed D antigen) to the nonnative form (termed C antigen) (14, 15). This conforma-
tional switch is of particular importance as the nonnative antigen is a poor inducer of
neutralizing antibodies and, therefore, is incapable of providing a long-lasting, protec-
tive immune response against PV (15–17). Therefore, any attempts to produce PV VLPs
must also attempt to ensure the particles maintain the D antigenic form.
PV VLPs have been produced in a number of different expression systems, including
mammalian, plant, and insect cells (18–22). Although the secretion of VLPs from insect
cells is an attractive option, each of these systems can incur high production costs,
making them less accessible for lower- to middle-income countries (LMICs). Yeast is a
heterologous expression system with potential for technology transfer to LMICs, as it is
inexpensive in terms of medium costs and infrastructure requirements. Additionally,
yeast expression is currently licensed for the production of human vaccines against two
viral pathogens, hepatitis B virus and human papillomavirus (23–25).
Using P1 sequences from the wt and a previously characterized mutant, we show
that PV VLPs can be produced in the yeast Pichia pastoris via three different expression
constructs. The expression of the potentially cytotoxic 3CD is modulated using different
molecular biology approaches. The VLPs produced from each construct show physical
properties similar to those of the ECs produced naturally during infection. Additionally,
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through two-dimensional (2D) class averaging of electron microscopy data, we show
that PV VLPs produced from each expression cassette maintain the classic icosahedral
morphology associated with picornavirus capsids, highlighting the potential of Pichia
pastoris as a model system for the production of enterovirus VLPs.
RESULTS
Correct processing of PV P1 in Pichia pastoris. To determine the feasibility of
producing enterovirus VLPs in Pichia, using PV as an exemplar, we employed three
different expression cassettes, as described for Fig. 1B, each containing the P1 region
together with the viral protease. Expression should result in the production of VP0, VP1,
and VP3 and assembly into VLPs. A dual promoter expression system previously was
used to produce VLPs for other enteroviruses, such as coxsackie A6, coxsackie A16, and
enterovirus A71 (26–28). We employed this approach here for the wt and for a
previously described capsid mutant of PV-1 Mahoney (PV57), which we have shown to
increase D antigen stability in mammalian cell culture (29). Due to concerns over the
FIG 1 Schematic of the poliovirus genome, Pichia expression systems, and correct processing of PV P1. (A) Schematic of the poliovirus genome highlighting
the P1 structural region and the nonstructural proteins, including the viral protease 3CD. UTR, untranslated region; ssRNA, single-stranded RNA. (B) Schematic
of the pPink HC plasmid and the position in which the different expression constructs were cloned. (C) Immunoblot for PV VP1 and 3D. The virus control sample
was prepared from HeLa cell lysates 8 h postinfection. Yeast samples were collected 48 h postinduction and lysed using 0.1 M NaOH. All samples were boiled
in 2 Laemmli buffer and separated by SDS-PAGE prior to analysis by immunoblotting using mouse monoclonal -VP1 and rabbit monoclonal -3D antibody.
Two exposures of the same -3D immunoblot are shown to aid interpretation.
Production of Poliovirus VLPs
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potential toxicity of the viral protease 3CD, we modulated the level of 3CD expression
to investigate its impact on VLP production (30). To this end, we designed two other
constructs for comparative analysis alongside the dual promoter, using PV57 (Fig. 1B).
To modulate the expression of 3CD, we introduced either the Thosea asigna virus
(TaV) 2A peptide sequence between the end of P1 and the start of 3CD or the
intergenic region internal ribosome entry site (IGR IRES; referred to as RhPV IRES) from
Rhopalosiphum padi virus (RhPV) between P1 and 3CD. TaV 2A peptide has one of the
most efﬁcient cleavage sequences, which should lead to a ratio of P1 to 3CD between
1:1 and 2:1, depending on the efﬁciency of translation reinitiation (31). The introduction
of the RhPV IRES should have a more pronounced impact on the levels of 3CD, as
IRES-mediated translation has been shown to be 5- to 20-fold lower than cap-driven
translation (32).
Following transformation, Pichia colonies were tested for expression levels. Follow-
ing 48 h of induction, samples from small-scale test expression were indirectly analyzed
for the correct processing of P1 polyprotein using an anti-VP1 antibody (Fig. 1C). The
anti-VP1 immunoblot showed that material derived from all three expression cassettes
correctly processed P1, resulting in the appearance of an immunoreactive protein
similar in size to the VP1 produced in PV-1 Mahoney-infected HeLa cell lysate, while the
vector-only Pichia control (HC only) showed no reactivity. The VP1 band for PV57-2A-
3CD showed a small mobility shift, reﬂecting the 18-amino-acid extension to the C
terminus of VP1. These lysates were also probed with anti-3D, which showed two major
bands, at approximately 72 and 55 kDa, corresponding to the expected sizes of 3CD
and 3D (Fig. 1C). The anti-3D immunoblot showed similar levels of 3CD expression
between the dual promoter and 2A expression cassettes; however, as expected, the
IRES-mediated 3CD expression was much lower.
Material produced in Pichia pastoris sedimented similarly to PV-1 empty cap-
sids. The best-expressing Pichia clones for each expression system then were induced
using 0.5% methanol in a 200-ml culture volume, and cell pellets collected 48 h
postinduction for puriﬁcation. To determine whether each of the different expression
systems produced higher-order structures, the cell pellets were homogenized at
275 MPa and subjected to multistep centrifugal puriﬁcation, culminating in separa-
tion through 15 to 45% sucrose gradients. Gradient fractions then were analyzed for the
presence of VP1 by immunoblot assay (Fig. 2). As expected, the HC vector-only sample
was not positive for VP1, whereas the expression cassettes for wt DP, PV57 DP, and
FIG 2 Puriﬁcation of virions and VLPs. All samples were puriﬁed by ultracentrifugation and fractioned
from top to bottom in 1-ml aliquots. A 12-l sample from each fraction then was taken and boiled in 5
Laemmli buffer and separated by SDS-PAGE prior to analysis by immunoblotting using mouse mono-
clonal -VP1. Shown is a representative example of three separate experiments for each construct.
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PV57-IRES-3CD produced material that peaked in fraction 6. For PV57-2A-3CD, the
peak was slightly further down the gradient (in fraction 7). As a control, PV-1 Mahoney
virus also was puriﬁed through a 15 to 45% sucrose gradient and probed for VP-1 by
immunoblotting, and it showed two distinct populations, as expected (29), correspond-
ing to peaks for ECs in fractions 4 and 5 and infectious virions in fractions 8 and 9.
Pichia-derived VLPs are structurally similar to infectious PV. Although the
density gradient puriﬁcation suggested that the viral protein produced assembled as
VLPs, we sought to conﬁrm this by electron microscopy (EM) and 2D class averaging.
Figure 3a shows a representative micrograph of Pichia-derived VLPs from each expres-
sion cassette compared with gradient-puriﬁed infectious PV. The negative-stain EM
images show Pichia-derived VLPs to be of morphology similar to that of PV particles
produced by mammalian cells. The VLPs were similar in diameter across both wt and
PV57 VLPs as well as between the different expression cassettes (33.4  1.40 nm
[n 20]). The diameters of the Pichia-derived VLPs were very similar to the diameter of
infectious PV virions (33.5  0.56 nm [n 20]). In the micrographs of PV57 samples,
small particles, depicted by the red arrows, far outnumbered the larger 33-nm
particles, suggesting an assembly defect for this mutant.
The larger particles (white arrows) then were analyzed by 2D classiﬁcation (Fig. 3b).
Class averages were highly indicative of icosahedral structure for both the Pichia-
derived VLPs and PV virions. This analysis also showed the VLPs tended to be more
angular in shape than the PV virions, indicating that they are in the nonnative
conformation. Native (D antigenic) particles are known to be smoother in appearance,
as seen in the class averages for PV virions (33, 34). However, the classes show variation
in both the size and shape for all expression cassettes, suggesting a level of hetero-
FIG 3 Electron microscopy and 2D class averages of PV VLPs. (a) Representative micrographs from different preparations of PV VLPs and
infectious PV (PV-1). White arrowheads indicate33-nm-diameter particles. Red arrowheads indicate smaller particles (22-nm diameter).
Scale bar shows 100 nm. (b) 2D class averages from the twenty most populated classes of 33-nm-diameter particles in each data set,
following removal of the smaller particles. Class averages are shown with a sigma contrast of 3. Average particle size, n 20 for each
preparation.
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geneity in the Pichia-derived VLPs. Interestingly, the addition of 2A to the C terminus
of VP1 did not lead to overall changes in particle morphology that could be determined
by negative-stain EM.
Pichia-derived VLPs did not package substantial levels of nucleic acid. To
further determine that the VLPs produced in Pichia were empty and had not packaged
cognate mRNA or any nonspeciﬁc yeast RNA, the peak fraction for each expression
cassette was pelleted at 151,000 g and resuspended in phosphate-buffered saline
(PBS) and 20 mM EDTA prior to analysis at absorbance wavelengths of 260 nm and
280 nm. The 260/280 nm ratios shown in Table 1 indicate that the level of nucleic acid
present in the VLP samples was very low. This suggests that the VLPs produced in Pichia
are reminiscent of ECs produced during mammalian cell infection, which contain no
nucleic acid (35).
PV57 shows no improvement in D antigen content. Following the observation
that Pichia-derived VLPs showed characteristics similar to those of ECs, we next
determined their antigenic character by enzyme-linked immunosorbent assay (ELISA).
We analyzed gradient fractions using a standard protocol, as established by the
National Institute for Biological Standards and Control (NIBSC), using the current
inactivated vaccine (BRP) as a positive control (36).
Reagents speciﬁc to C antigen revealed that both wt DP and PV57 DP VLPs produced
large amounts of C antigen, whereas the PV57-2A-3CD and PV57-IRES-3CD VLPs were
below the threshold of detection (Fig. 4). This suggests that despite VLPs being processed
correctly and detectable by immunoblotting, these two expression systems are less efﬁcient
for VLP production than the dual promoter system. However, neither the wt nor any of the
PV57 VLPs contained detectable D antigen in this assay. As expected, the HC-only control
gradient fractions were negative for both D and C antigenic forms.
DISCUSSION
As we move toward the eradication of poliovirus, the number of cVDPV cases is
now outnumbering the number of paralytic polio cases caused by wt PV (http://
polioeradication.org/polio-today/polio-now/). However, both OPV and IPV require the
TABLE 1 Absorbance at 260/280 nma
Sample Absorbance at 260/280 nm
PV-1 infectious virus 1.54
HC only 0.80
WT DP 1.04
PV57 DP 0.75
PV57 2A 3CD 0.81
PV57 IRES 3CD 0.79
aPeak gradient fractions were pelleted and resuspended in PBS plus 20mM EDTA. Samples were analyzed for
absorbance at wavelengths of both 260 and 280 nm using NanoDrop One (Thermo Scientiﬁc).
FIG 4 Antigenicity of Pichia-derived VLPs. Shown are the antigenicity of Pichia-derived PV-1 wt and PV57 VLPs
and the reactivity of gradient fractions with MAb 1588 (C antigen) and MAb 234 (D antigen) in ELISA. The pink
dashed line represents the positive control, BRP, for the D antigen ELISA. The optical density at 492 nm (OD 492 nm)
is represented in arbitrary units (n 2).
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production of large amounts of infectious virus, which raises biosafety concerns around
the potential for the reintroduction of PV to the environment (1, 4). Therefore, as we
edge closer to a polio-free world, we need to consider alternative vaccine production
strategies to ensure control of PV is maintained. One solution is to produce a virus-free
VLP vaccine using a heterologous expression system. This approach has been success-
ful for the production of PV VLPs in both plant and insect cell systems, but both of these
require specialist equipment, which increases the cost of production, making it difﬁcult
to translate these production methods to LMICs (18–20). Yeast offers an alternative
heterologous expression system that can produce levels of protein production similar
to those of mammalian cells (e.g., 400 mg/liter compared to 500 mg/liter from mam-
malian cells [37]) but at a fraction of the cost and with the added advantages of greater
speed and ease of scalability (37–39). Therefore, we looked to build on the previous
work of Rombaut and Jore by producing PV VLPs in yeast to determine if this is a viable
expression system for future enterovirus vaccine production, especially in light of the
recent emergence of the neurovirulent enterovirus D68 as well as the increasing cases
of enterovirus A71 and coxsackievirus A16, the etiological agents of hand, foot, and
mouth disease (40–42).
First, we investigated the production of PV VLPs using a range of expression
cassettes. The dual promoter expression cassette was used previously for the produc-
tion of other picornavirus VLPs, while the introduction of TaV 2A and RhPV IRES was
used to modulate the expression of 3CD (26–28). 3C protease previously was shown to
have a toxic effect on cell viability, whereas 3CD was shown to be the active protease
in P1 processing and should be less toxic than 3C (8, 30). Therefore, in an attempt to
reduce protease toxicity, we introduced a previously characterized noncleavable 3CD
into our expression constructs (43). However, as shown in Fig. 1C, there is clear cleavage
of 3CD, suggesting that the noncleavable phenotype is expression system dependent.
Presumably, a host protease is responsible for the 3CD cleavage seen, which occurs at
a sequence close to the natural cleavage site. It would be interesting to fully ablate this
cleavage event in Pichia or introduce mutations into 3Cpro to reduce toxicity, as shown
previously for foot-and-mouth disease virus, and determine the impact of these mod-
iﬁcations on VLP production (44). We demonstrated that all three expression cassettes
led to the correct processing of P1 through the detection of VP-1 using monoclonal
antibody (MAb) 8650. This antibody also can detect full-length P1 and other processing
intermediates; however, we detected no structural precursors by immunoblotting,
suggesting good P1 processing efﬁciency in each expression cassette. Additionally, we
also showed that both the TaV 2A and RhPV IRES were able to control 3CD translation
in Pichia. These could be important tools for the production of VLPs from other virus
families, such as ﬂaviviruses or orthomyxoviruses, which may require differential ex-
pression of constructs required for protein maturation (45, 46).
The production of VLPs from each expression cassette was determined by density
gradient centrifugation and further conﬁrmed by negative-stain EM. The VLPs all
showed rates of sedimentation similar to that of the ECs produced from virus infection
of mammalian cells. Interestingly, the peak produced from the PV57-2A-3CD VLPs was
detected one fraction further down the gradient than the other VLPs. These VLPs were
assembled with an additional 20-amino-acid extension present on the C terminus of
VP1, suggesting the 2A peptide has an impact on the sedimentation rate of VLPs.
To ensure that no host RNA or cognate mRNA was being nonselectively packaged
into the VLPs, we used the 260/280-nm absorbance ratio to estimate the level of nucleic
acid present in the puriﬁed VLPs. The ratio of nucleic acid to protein was far lower than
that in the puriﬁed infectious virus and was similar to the levels of nucleic acid found
in equivalent fractions in the vector-only puriﬁed yeast lysate, suggesting that the VLPs
did not encapsidate substantial quantities of nonspeciﬁc nucleic acid.
2D particle analysis showed that all the expression cassettes produced icosahedral
particles of 33 nm in diameter. Given that negative staining leads to an overestima-
tion of particle size, these are very similar to the sizes of virions produced from natural
infection (47). The micrographs also highlighted a number of smaller particles puriﬁed
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along with PV57 VLPs, whereas these contaminating particles were rarely seen in the
wt VLP puriﬁcations. These small particles may represent assembly defects for the
PV57 mutant, leading to partially assembled particles. If so, these defects could be
alleviated by the coexpression of HSP-90, which previously was shown to be beneﬁcial
for PV capsid assembly (48). Alternatively, these particles could be contaminants, which,
for example, could be derived from yeast chaperones or enzyme complexes that
copurify with PV57 for unknown reasons.
Unfortunately, the VLPs produced in this study were in the nonnative conformation,
as highlighted by ELISA (Fig. 4), and the clear conformational difference between the
Pichia-derived VLPs and the PV virions was apparent by 2D classiﬁcation (Fig. 3b).
Although this was expected for the wt sequence, it was surprising for PV57. The PV57
mutant previously was shown to produce ECs in both C and D antigenic conformations
in mammalian cells by immunoprecipitation (29). It is clear that the ELISA may not
detect lower levels of antigen, as illustrated by no detection of either PV57-2A-3CD or
PV57-IRES-3CD here. These data also suggest that the alternative, dual promoter
expression cassette should be the primary choice for the production of other entero-
virus VLPs. Although we cannot be certain that the Pichia-derived VLPs produced here
would not lead to a protective immune response, the observation that these are
positive for C antigen suggests that they are poor inducers of neutralizing antibodies
and, therefore, are unlikely to induce protective immune responses (15–17). The lack of
pocket factor or the incorporation of a suboptimal molecule also could be responsible
for the dominance of the C conformation. Pocket factor has been identiﬁed as a small
lipid moiety that binds in a hydrophobic cleft in VP1 (47). This molecule contributes to
maintaining capsid stability and is displaced during receptor binding and consequent
conformational changes associated with the cell entry process. Capsids produced in
mammalian cells have a natural pocket factor; however, it is unclear whether VLPs
produced in heterologous expression systems bind a cofactor that occupies the pocket.
Structural analysis by cryo-EM of plant-derived PV VLPs failed to demonstrate the
presence of pocket factor, suggesting that pocket-binding lipids can be expression
system dependent (18). Additionally, Rombaut and Jore (40) found that wt PV VLPs
produced in Saccharomyces cerevisiae required the addition of pocket binding com-
pounds to maintain the native conformation, suggesting either the absence of pocket
factor or the incorporation of a pocket factor with low binding afﬁnity, which was easily
displaced through the addition of pocket binding compounds.
In conclusion, we believe we have shown that Pichia pastoris is a viable expression
system for large-scale production of PV VLPs, which share characteristics with ECs
produced from mammalian cells. In accordance with other studies, we have shown that
a dual promoter expression system is the most efﬁcient way of producing picornavirus
VLPs. Additionally, we also demonstrated translational control over protein expression
levels through the use of molecular biology approaches, utilizing the TaV 2A peptide
and the RhPV IRES. Although the PV57 VLPs used here were shown to have stability
superior to that of the wt when produced in a mammalian system, the stabilization did
not extend to particles expressed in yeast, possibly for the reasons outlined above.
However, in preliminary experiments using the thermostable mutants previously char-
acterized by Fox et al. (18, 20, 49), we have shown Pichia to be capable of efﬁciently
producing D antigen. Therefore, we believe that this system has the potential to
produce a VLP vaccine not only for a polio-free world but also as a model system for
enterovirus VLP vaccine production.
MATERIALS AND METHODS
Cells and viruses. HeLa cells were obtained from the National Institute of Biological Standards and
Controls (NIBSC), UK. PichiaPink yeast strain one (Invitrogen, USA) was grown according to the instruc-
tions of the manufacturer. The cDNA of wt PV-1 (Mahoney strain) used in this study was sourced from
Bert Semler, University of California, and was cloned downstream of a T7 RNA promoter to allow in vitro
RNA synthesis. A hammerhead ribozyme was included at the 5= end, resulting in the production of
authentic infectious PV-1 RNA (10). To initiate infection, L cells (which lack the PV receptor CD155) were
transfected with PV-1 RNA, and the resulting viruses were propagated in HeLa cells.
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Vector construction. The P1 genes of PV-1 Mahoney and PV57 were optimized according to P.
pastoris preferred codon usage, synthesized (GeneART), and inserted into the pPink-HC expression vector
multiple cloning site (MCS) using EcoRI and FseI (New England Biolabs [NEB]). The 3CD gene was also
codon optimized for P. pastoris and designed to include a noncleavable sequence to reduce the potential
toxic effects of 3C in a heterologous expression system (43). The 3CD gene then was cloned into the
pPink-HC expression vector MCS using EcoRI and FseI (NEB). For the coexpression of P1 and 3CD, a
number of approaches were taken. For the dual promoter constructs, the region from position 1 of the
3CD pPink-HC to position 1285 was ampliﬁed by PCR, with the primers inserting a SacII restriction site
at both the 5= and 3= ends of the product. The P1 expression plasmid was linearized by SacII (NEB), and
then the 3CD PCR product was inserted into SacII-linearized P1 plasmid. Clones then were screened for
directionality, ensuring the promoters for each protein were in the correct orientation. The PV57-2A-
3CD plasmid was constructed through a series of overlapping PCRs. Brieﬂy, the TaV 2A peptide sequence
was inserted upstream of 3CD through overlapping PCR. A second PCR produced the PV57 P1 with a
3= nucleotide tail designed to be complementary to the 5= sequence of TaV 2A. These two products then
served to prime each other, in a third PCR, for 10 cycles prior to the addition of external primers. This PCR
product then was inserted into pPink-HC using EcoRI and FseI (NEB). The RhPV IGR IRES (50) (GenBank
accession no. AF022937.1, nucleotides 6576 to 7103) was synthesized (GeneART). The PV57-IRES-3CD
also was introduced by overlapping PCR using the same steps as those described for PV57 TaV 2A. All
PCR steps were carried out with Phusion polymerase (NEB) using the manufacturer’s guidelines.
Yeast transformation and induction. Plasmids were linearized by AﬂII digestion and then trans-
formed into PichiaPink strain one (Invitrogen) by electroporation. The transformed yeast cells were
plated on Pichia adenine dropout (PAD) selection plates that lacked adenine and incubated at 28°C until
sufﬁcient numbers of white colonies appeared (3 to 5 days). To screen for high-expression clones, 8
colonies were randomly selected for small-scale expression experiments. Brieﬂy, colonies were cultured
in yeast extract-peptone-dextrose (YPD) for 48 h at 28°C with shaking at 250 rpm and then pelleted at
1,500 g, resuspended in yeast extract-peptone-methanol (YPM; 0.5%, vol/vol, methanol) to induce
protein expression, and cultured for a further 48 h. Cultures were fed methanol to 0.5% (vol/vol) 24 h
postinduction. To determine the expression levels of each clone, the samples were analyzed by Western
blotting as described below. For VLP production, a stab from a previously expressing glycerol stock was
cultured for 48 h in YPD to high density. To increase biomass, 2 ml of the starter culture was added to
200 ml YPD in a 2-liter bafﬂed ﬂask and cultured at 28°C at 250 rpm for a further 24 h. Cells were pelleted
at 1,500 g, resuspended in 200 ml YPM (0.5%, vol/vol, methanol), and cultured for a further 48 h.
Cultures were fed methanol to 0.5% (vol/vol) 24 h postinduction. After 48 h, cells were pelleted at
2,000 g and resuspended in breaking buffer (50 mM sodium phosphate, 5% glycerol, 1 mM EDTA, pH
7.4) and frozen prior to processing.
Sample preparation and Western blotting. Cell-cultured virus supernatant samples were prepared
through a 1:1 mixture with 2 Laemmli buffer and heated to 95°C for 3 min. For Pichia-derived protein
samples, 100 l culture was centrifuged at 2,000 g for 5 min and resuspended in 100 l 0.1 M NaOH
for 5 min before being centrifuged at 2,000 g for a further 5 min. Cell pellets then were resuspended
in 2 Laemmli buffer and heated to 95°C for 3 min. Gradient fraction samples were prepared through
a 1:5 mixture with 5 Laemmli buffer. Protein extracts were analyzed by 12% (wt/vol) SDS-PAGE using
standard protocols. Western blot analyses were performed using a monoclonal primary antibody against
VP1 protein (MAb 8560; Millipore), followed by detection with a goat anti-mouse secondary antibody
conjugated to horseradish peroxidase, and developed using a chemiluminescent substrate (Promega). To
identify viral protease 3CD, a rabbit polyclonal antibody was used, followed by detection with a goat
anti-rabbit secondary antibody conjugated to horseradish peroxidase, and developed using a chemilu-
minescent substrate (Promega) (51).
Puriﬁcation of PV and PV VLPs. Virus-infected HeLa cells were freeze-thawed and clariﬁed by
differential centrifugation. Supernatant was collected and virus pelleted through a 30% (wt/vol) sucrose
cushion at 151,000 g (using a Beckman SW 32 Ti rotor) for 3.5 h at 10°C. Virus pellet was resuspended
in phosphate-buffered saline (PBS) and clariﬁed by differential centrifugation. Supernatant was puriﬁed
through 15 to 45% (wt/vol) sucrose density gradient by ultracentrifugation at 151,000 g (using a
Beckman SW 40 rotor) for 3 h at 10°C (14). Pichia cell suspensions were thawed and subjected to cell lysis
using CF-1 cell disruptor at275 MPa and chilled to 4°C following the addition of 0.1% Triton X-100. The
resulting lysate then was centrifuged at 4,000 rpm to remove the larger cell debris, followed by a
10,000 g spin to remove further insoluble material. The supernatant then was nuclease treated using
25 U/ml HS-nuclease (2BScientiﬁc) for 1.5 h at room temperature with gentle agitation. The supernatant
then was mixed with saturated ammonium sulfate (40%, vol/vol) and incubated at 4°C overnight. The
precipitated protein was pelleted at 4,000 rpm and resuspended in PBS plus 0.1% Triton X-100. The
solution then was pelleted at 10,000 g to remove any insoluble material. The supernatant was
collected and pelleted through a 30% (wt/vol) sucrose cushion at 151,000 g (using a Beckman SW 32
Ti rotor) for 3.5 h at 10°C. The resulting pellet was resuspended in PBS plus 0.1% Triton X-100 and clariﬁed
by centrifugation at 10,000 g. Supernatant was puriﬁed through a 15 to 45% (wt/vol) sucrose density
gradient by ultracentrifugation at 151,000 g (using a Beckman SW 40 rotor) for 3 h at 10°C (14).
Gradients were collected in 1-ml fractions from top to bottom and analyzed for the presence of VLPs
through Western blotting and ELISA.
ELISA. A noncompetitive sandwich ELISA was used to measure PV-1 D and C antigen content (36).
Brieﬂy, 2-fold dilutions of antigen were captured using a PV-1-speciﬁc polyclonal antibody and then
detected using PV-1-speciﬁc D antigen (MAb 234)- or C antigen (MAb 1588)-speciﬁc monoclonal
antibody (kindly provided by NIBSC), followed by anti-mouse peroxidase conjugate (52, 53). BRP was
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used as the standard for D antigen content in each ELISA, which then was analyzed through a Biotek
PowerWave XS2 plate reader.
Electron microscopy. To prepare samples for negative-stain transmission EM, carbon-coated 300-
mesh copper grids (Agar Scientiﬁc, UK) were glow discharged in air at 10 mA for 30 s. Three-microliter
aliquots of puriﬁed VLP/virus stocks were applied to the grids for 30 s, and then excess liquid was
removed by blotting. To improve the concentration of particles on the grid surface, a second 3-l aliquot
was applied for a further 30 s, and then grids were washed twice with 10 l distilled H2O. Grids were
stained with 10 l 1% uranyl acetate solution, which was promptly removed by blotting before another
application of 10 l 1% uranyl acetate solution for 30 s. Grids were subsequently blotted to leave a thin
ﬁlm of stain and then air dried. EM was performed using an FEI Tecnai F20 transmission electron
microscope (operating at 200 kV with a ﬁeld emission gun) with an FEI CETA CMOS charge-coupled
device camera (Astbury Biostructure Laboratory, University of Leeds). Samples were imaged across a
range of defocus values (2.0 m to 3.8 m) at a nominal magniﬁcation of 25,000, resulting in an
object sampling of 0.418 nm/pixel.
Image processing. Raw micrographs were visualized with ImageJ, 1.51d (54, 55). The measuring tool
of ImageJ was used to calculate VLP/virion diameter; three separate measurements were taken and
averaged to give a diameter for each VLP/virion.
The RELION-3.0 pipeline (56–58) was used for further image processing of EM data. To generate
templates for automated particle picking, a subset of particles was manually picked, extracted, and then
classiﬁed by reference-free 2D classiﬁcation. Automated particle picking resulted in large numbers of
“junk” particles (corresponding to overlapping VLPs, disassembled VLPs, and other contaminants), which
were removed by excluding poor-quality classes from a single round of reference-free 2D classiﬁcation.
Particles from the remaining classes were subjected to another round of reference-free 2D classiﬁcation,
and the resultant class averages were inspected. For each round of 2D classiﬁcation, a regularization
parameter of 2 was speciﬁed, and classiﬁcation was allowed to proceed for 25 iterations. No symmetry
was imposed during the 2D classiﬁcation.
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